JP2022532556A5 - - Google Patents
Info
- Publication number
- JP2022532556A5 JP2022532556A5 JP2021566149A JP2021566149A JP2022532556A5 JP 2022532556 A5 JP2022532556 A5 JP 2022532556A5 JP 2021566149 A JP2021566149 A JP 2021566149A JP 2021566149 A JP2021566149 A JP 2021566149A JP 2022532556 A5 JP2022532556 A5 JP 2022532556A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- domain
- polypeptide
- item
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020891A JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845306P | 2019-05-08 | 2019-05-08 | |
| US62/845,306 | 2019-05-08 | ||
| PCT/US2020/031781 WO2020227475A1 (en) | 2019-05-08 | 2020-05-07 | Cll-1 targeted immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020891A Division JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532556A JP2022532556A (ja) | 2022-07-15 |
| JP2022532556A5 true JP2022532556A5 (enExample) | 2023-05-15 |
Family
ID=73051177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566149A Pending JP2022532556A (ja) | 2019-05-08 | 2020-05-07 | Ｃｌｌ－１標的免疫療法 |
| JP2025020891A Pending JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020891A Pending JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12421315B2 (enExample) |
| EP (1) | EP3966249A4 (enExample) |
| JP (2) | JP2022532556A (enExample) |
| KR (1) | KR20220031549A (enExample) |
| CN (1) | CN114502586B (enExample) |
| AU (1) | AU2020267639A1 (enExample) |
| BR (1) | BR112021022365A2 (enExample) |
| CA (1) | CA3148027A1 (enExample) |
| IL (1) | IL287769A (enExample) |
| MA (1) | MA55905A (enExample) |
| MX (1) | MX2021013590A (enExample) |
| SG (1) | SG11202111927QA (enExample) |
| WO (1) | WO2020227475A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123938A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20220004751A (ko) * | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| WO2020227475A1 (en) | 2019-05-08 | 2020-11-12 | Bluebird Bio, Inc. | Cll-1 targeted immunotherapies |
| AU2023248532A1 (en) * | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
| CN115772222B (zh) * | 2022-12-16 | 2024-03-29 | 浙江康佰裕生物科技有限公司 | 抗cll1单域抗体及其应用 |
| KR102908421B1 (ko) | 2025-04-16 | 2026-01-12 | (주)주인정보시스템 | 인공지능 기반 빌딩 자동제어 시스템 및 그 방법 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| CA2128511C (en) | 1992-01-23 | 2006-11-07 | Andreas Pluckthun | Monomeric and dimeric antibody-fragment fusion proteins |
| US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| HUT73101A (en) | 1993-02-12 | 1996-06-28 | Harvard College | Method for regulating transcription of targeted genes and other biological events |
| EP0737207B1 (en) | 1994-01-11 | 2004-09-22 | Dyax Corporation | Inhibitors of human plasmin derived from the kunitz domains |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| ATE423140T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| WO2010062966A2 (en) | 2008-11-26 | 2010-06-03 | The General Hospital Corporation | Methods for inducing mixed chimerism |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| JP5897035B2 (ja) | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド，ボルチモア | 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法 |
| BR112015006824A2 (pt) | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| HK1220111A1 (zh) | 2013-03-05 | 2017-04-28 | Baylor College Of Medicine | 人类t淋巴细胞中类肝素酶的表达 |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| JP6966330B2 (ja) * | 2015-05-01 | 2021-11-17 | インヒブルクス，インコーポレイティド | Ｉｉｉ型分泌装置標的化分子 |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| JP6894430B2 (ja) * | 2015-08-24 | 2021-06-30 | セレクティスＣｅｌｌｅｃｔｉｓ | 統合された制御機能を有するキメラ抗原受容体 |
| EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| CA3020993A1 (en) | 2016-04-14 | 2017-10-19 | Bluebird Bio, Inc. | Salvage chimeric antigen receptor systems |
| CA3084551A1 (en) | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
| CN111819682B (zh) | 2018-03-26 | 2025-04-29 | 三菱综合材料株式会社 | 绝缘电路基板用接合体的制造方法及绝缘电路基板用接合体 |
| WO2020052543A1 (en) | 2018-09-10 | 2020-03-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against cd33 and constructs thereof |
| WO2020113063A1 (en) | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Single domain antibodies against cll-1 |
| WO2020123933A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| AU2019397152A1 (en) | 2018-12-14 | 2021-06-24 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2020123938A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| EP3966338A1 (en) | 2019-05-08 | 2022-03-16 | Inhibrx, Inc. | Cd123 targeted immunotherapies |
| WO2020227475A1 (en) | 2019-05-08 | 2020-11-12 | Bluebird Bio, Inc. | Cll-1 targeted immunotherapies |
| KR20220070501A (ko) | 2019-09-30 | 2022-05-31 | 2세븐티 바이오, 인코포레이티드 | 이량체화제로 조절된 면역수용체 복합체 |
| WO2021207613A1 (en) | 2020-04-10 | 2021-10-14 | 2Seventy Bio, Inc. | Frb antibodies |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
-
2020
- 2020-05-07 WO PCT/US2020/031781 patent/WO2020227475A1/en not_active Ceased
- 2020-05-07 SG SG11202111927QA patent/SG11202111927QA/en unknown
- 2020-05-07 EP EP20801987.7A patent/EP3966249A4/en active Pending
- 2020-05-07 KR KR1020217039632A patent/KR20220031549A/ko not_active Ceased
- 2020-05-07 MX MX2021013590A patent/MX2021013590A/es unknown
- 2020-05-07 BR BR112021022365A patent/BR112021022365A2/pt unknown
- 2020-05-07 CA CA3148027A patent/CA3148027A1/en active Pending
- 2020-05-07 MA MA055905A patent/MA55905A/fr unknown
- 2020-05-07 AU AU2020267639A patent/AU2020267639A1/en active Pending
- 2020-05-07 CN CN202080049880.5A patent/CN114502586B/zh active Active
- 2020-05-07 JP JP2021566149A patent/JP2022532556A/ja active Pending
- 2020-05-07 US US17/608,738 patent/US12421315B2/en active Active
-
2021
- 2021-11-01 IL IL287769A patent/IL287769A/en unknown
-
2025
- 2025-02-12 JP JP2025020891A patent/JP2025081414A/ja active Pending
- 2025-08-27 US US19/311,186 patent/US20260055192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531719A5 (enExample) | ||
| CN113784732B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| CN113784733B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| Bartkowiak et al. | 4-1BB agonists: multi-potent potentiators of tumor immunity | |
| JP2025511872A5 (enExample) | ||
| AU2016228080B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| Tang et al. | T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo | |
| CN111051502B (zh) | 通用型嵌合抗原受体t细胞制备技术 | |
| JP2022532557A5 (enExample) | ||
| EP3250695A1 (en) | Universal immune cells for cancer immunotherapy | |
| EP2632482A2 (en) | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies | |
| JP2022537159A5 (enExample) | ||
| Pircher et al. | T cell engineering | |
| JP2022513460A5 (enExample) | ||
| WO2019223226A1 (zh) | 改良型抗cd19 car-t细胞 | |
| CN117844761A (zh) | 逆转肿瘤微环境的融合蛋白及其应用 | |
| WO2017024440A1 (zh) | 含Toll样受体胞内结构域的嵌合抗原受体 | |
| CN110257338B (zh) | 嵌合细胞因子受体 | |
| RU2020122708A (ru) | Рецепторы nkg2d daric | |
| Wu et al. | Immunotherapies: the blockade of inhibitory signals | |
| JP2025513801A5 (enExample) | ||
| JP2025081414A5 (enExample) | ||
| CN113330038A (zh) | Cd20组合靶向的工程化免疫细胞 | |
| JP2017081836A (ja) | 細胞傷害性ｔ細胞の作製方法 |